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Biotransformation Strategy To Reduce Allergens in Propolis
Claudio Gardana,a Andrea Barbieri,b Paolo Simonetti,a and Simone Guglielmettib
Division of Nutritiona and Division of Food Microbiology and Bioprocesses,b Department of Food, Environmental and Nutritional Sciences (DeFENS), Universita` degli Studi
di Milano, Milan, Italy
Propolis (bee glue) is a resinous, sticky, dark-colored material produced by honeybees. Propolis today, due to its medicinal prop-
erties, is increasingly popular and is extensively used in food, beverages, and cosmetic products. Besides its numerous positive
properties, propolis may also have adverse effects, such as, principally, allergic eczematous contact dermatitis in apiarists and in
consumers with an allergic predisposition. In this study, we found appropriate conditions for removing caffeate esters, which are
the main allergenic components, from raw propolis. The proposed method consists of the resuspension of propolis in a food
grade solvent, followed by a biotransformation based on the cinnamoyl esterase activity of Lactobacillus helveticus. We showed
that the reduction of caffeate esters by L. helveticus did not affect the content of flavonoids, which are the main bioactive mole-
cules of propolis. Furthermore, we verified that the biotransformation of propolis did not cause a loss of antimicrobial activity.
Finally, we demonstrated that the ability of L. helveticus to hydrolyze caffeate esters in propolis is strain specific. In conclusion,
the proposed strategy is simple, employs food grade materials, and is effective in selectively removing allergenic molecules with-
out affecting the bioactive fraction of propolis. This is the first study demonstrating that the allergenic caffeate esters of propolis
can be eliminated by means of a bacterial biotransformation procedure.
Propolis (bee glue) is a resinous, sticky, dark-colored materialproduced by honeybees (Apis mellifera), which collect exu-
dates from trees, mix them with wax, and use the resulting mate-
rial to seal and protect honeycombs. The chemical composition of
propolis varies anddependsmainly on the plants accessible to bees
and on the season. Propolis originating from plants of the genus
Populus (for instance, poplar), which are typical of the temperate
zones of Europe, China, and North America, comprises resins (20
to 25%), waxes (30 to 40%), volatile oils (5 to 10%), and many
phenolic compounds (10 to 30%), which include, in particular,
flavonoids. In addition, the phenolic fraction of propolis contains
aromatic acids, such as cinnamic, caffeic, ferulic, and p-coumaric
acids, and their esters (3).
The attribution of a potential medicinal value to propolis dates
back to ancient Egyptians, Greeks, and Romans, who used propo-
lis to heal wounds, sores, and ulcers (11). Registered as an official
drug in the London pharmacopeias of the 17th century, propolis
today, due to its medicinal properties, is increasingly popular and
is extensively used in food, beverages, and cosmetic products. In-
deed, the ethanolic extract of propolis reportedly has a wide vari-
ety of biological actions, including antimicrobial (18), antiherpes
and antifungal (20), anti-inflammatory (22), antioxidant (17),
immune-stimulating (19), cariostatic (8), anticancer (16), and
anti-Helicobacter pylori (1) activities. The pharmacological prop-
erties of propolis have been correlated with the presence of
specific molecules. For instance, its antibacterial and antiviral
activities have been linked with diterpenic acids and dihydro-
benzofuranic lignans, and its anti-inflammatory and antioxi-
dant activities seem to be due to flavonoids, whereas hepato-
protective and anticancer activities have been proposed for
several propolis constituents, including caffeoylquinic acid de-
rivatives and phenylethyl caffeate (4).
Besides the numerous above-mentioned positive effects,
propolis, though seemingly relatively safe (calculated safe dose,
1.4 mg per kg of body weight per day in humans [5]), may have
adverse effects, such as xerostomia, gastric pain, and allergic ec-
zematous contact dermatitis, in apiarists (10) and in consumers
with an allergic predisposition (23). Less than 10% of the popula-
tion is sensitive to propolis (sensitization rate, 1.2 to 6%); never-
theless, a significant increasing trend in sensitization has been ob-
served in adolescents in recent decades (from 2 to 13.7% in the
period 1995 to 2002) (15), possibly as a consequence of a consid-
erably augmented use of propolis in numerous commercial prod-
ucts. For this reason, a strategy to eliminate allergens from propo-
lis would be of wide interest. Nonetheless, to the best of our
knowledge, propolis with a high content of flavonoids and a re-
duced content of allergens is not industrially available at present.
In this context, we describe a strategy using food grade mate-
rials to selectively and effectively reduce the allergenic molecules
in propolis. The allergens in propolis are mainly caffeic acid (CA)
derivatives (14), and in this study, we show how to treat propolis
in order to eliminate these molecules by the cinnamoyl esterase
activity of a dairy bacterium, namely, Lactobacillus helveticus.
MATERIALS AND METHODS
Bacterial strains and culture conditions. L. helveticus strains were grown
overnight anaerobically at 42°C in MRS broth (Difco, Detroit, MI).
Propolis biotransformation. Raw propolis samples (collected from
the Puglia region of Italy) were chilled at 20°C (since it becomes hard
and very brittle at lower temperatures), finely ground in amill, and passed
through a 500-m (35-mesh) sieve. At the same time, the bacterial-cell
concentration of an overnight culture of L. helveticus was determined
microscopically with a Neubauer improved counting chamber (Marien-
feld GmbH, Lauda-Königshofen, Germany). Then, 1 g of propolis was
placed in each 50-ml tube in which we had previously pelleted different
amounts of L. helveticus cells (108 to 1014 bacterial cells). Finally, we added
2 ml of phosphate-buffered saline (PBS) (pH 7.3) containing ethanol
Received 12 March 2012 Accepted 2 April 2012
Published ahead of print 20 April 2012
Address correspondence to Simone Guglielmetti, simone.guglielmetti@unimi.it.
Copyright © 2012, American Society for Microbiology. All Rights Reserved.
doi:10.1128/AEM.00811-12
4654 aem.asm.org Applied and Environmental Microbiology p. 4654–4658 July 2012 Volume 78 Number 13
 o
n








(from 5 to 70%) or polyethylene glycol (PEG) 400 (from 1 to 80%). After
24 h of incubation at 37°C under constant agitation by a magnetic stirrer,
samples were collected and analyzed by liquid chromatography/mass
spectrometry. Bacterial-cell concentrations were also determined micro-
scopically with the counting chamber after incubation.
Analytical methods for the study of the phenolic fraction of propo-
lis. After biotransformation, phenolic fractions were extracted from
propolis samples and analyzed as described previously (9). In brief, we
added 70ml of ethyl acetate to the sample (bacteria-propolismixture) and
incubated it at room temperature under agitation for 10min. Themixture
was centrifuged at 1,500  g for 5 min, and the supernatant was trans-
ferred into a flask. The solid residue was extracted again with ethyl acetate
as described above. The extracts were dried under nitrogen, and the pellets
were dissolved in 100ml methanol. After a final centrifugation at 4,000
g for 1 min, the supernatants were diluted and analyzed by ultra-high-
performance liquid chromatography coupled with tandem mass spec-
trometry (UHPLC-MS/MS). UHPLC-MS/MS analyses were performed
with an Acquity UHPLC system (Waters, Milford, MA) coupled with a
Quattromicro triple-quadrupole mass spectrometer (Waters). A 1.7-m
C18 BEH Shield column (150 by 2.1 mm; Waters) was used for the sepa-
ration at a flow rate of 0.45 ml min1. The separation was carried out at
40°C with linear gradient elution (eluent A, 0.05% HCOOH; eluent B,
0.05%HCOOH in acetonitrile). The gradient was as follows: 20 to 30% B
in 4min, 30 to 40%B in 5min, 40 to 60%B in 3min, 60 to 90%B in 1min,
and then 90% B for 2 min. The capillary voltage was set to 2.7 kV, and the
cone voltage and the energy applied during fragmentation (Elab) were
specific for each compound, as previously reported (9). Allmass datawere
obtained in the negative ion mode. The source temperature was 130°C,
the desolvation temperature was 380°C, and argon was used at 0.21 Pa to
improve fragmentation in the collision cell. Masslinx 4.0 acquired data
with the Quan-Optimize option for the fragmentation study. The frag-
mentation transitions for the multiple-reaction monitoring (MRM) were
as previously reported (9). CA, 3-methyl-2-butenyl-CA (3M2B), internal
standard (dihydrocaffeic acid [DHCA]), and caffeic acid phenyl ethyl es-
ter (CAPE) were purchased from Sigma-Aldrich (St. Louis, MO). Methyl
caffeate was from Chromadex (Milan, Italy), ethyl caffeate from Water-
stone Technology (Carmel, IN), and ethyl ferulate from Santa Cruz Tech-
nology (Santa Cruz, CA).Methanol, acetonitrile, ethyl acetate, and formic
acid were supplied by Merck (Darmstadt, Germany). 2-Methyl-3-bute-
nyl-caffeate (2M3B), benzyl-caffeate (CABE), and 3-methyl-3-butenyl-
caffeate (3M3B) were synthesized as described previously (9). An un-
paired Student’s t test was run for statistically significant differences.
Antimicrobial assay. Antimicrobial activity was determined by the
agar dilution method on two different samples: (i) conventional propolis
extract (60% ethanol, 18.1 1.0 mg ml1 flavonoids, 7.1 0.4 mg ml1
phenolic acids [including 4.3  0.2 mg ml1 allergenic caffeate esters])
and (ii) MIMLh5-treated propolis extract (60% ethanol, 18.1  1.0 mg
ml1 flavonoids, 5.2 0.3 mg ml1 phenolic acids [including 1.5 0.2
mg ml1 allergenic caffeate esters]).
Furthermore, a 60% ethanol solution in water was used as a control.
The assay was performed against five indicator microorganisms: Staphy-
lococcus aureus (three strains), Staphylococcus haemolyticus (four strains),
Streptococcus pneumoniae (six strains), Candida albicans (eight strains),
and Candida tropicalis (six strains). Bacteria were cultivated in Mueller-
Hinton medium (Difco), whereas fungi were grown on Sabouraud’s dex-
trose medium (Difco). In brief, the samples were serially 2-fold diluted in
the range of 0.07 to 9.0 mg ml1 flavonoids (equally for the ethanol con-
trol) and spiked on agar plates. The agar plates had been previously inoc-
ulated with approximately 104 CFU of the indicator strain, whose cells
were collected at the mid-log phase of growth. The plates were read after
24 h of incubation at 37°C for bacteria and after 4 days at 35°C for fungi.
The MICs of samples promoting growth inhibition of 50% of the strains
under study were denoted MIC50s.
RESULTS AND DISCUSSION
A few methods have been proposed to obtain propolis with a
reduced proportion of allergenic substances. For instance, a recent
patent reported a protocol consisting of chemical-physical purifi-
cation steps to produce hypoallergenic propolis extracts (K.-H.
Sensch, 27 April 2009, international patent application WO2009/
133073). However, these methods come with several drawbacks,
such as altered taste, reduced polyphenol content, or high energy
consumption during production steps. The methods also lack se-
lectivity, and they cannot preserve the biological/pharmacological
efficacy of the extract obtained. In this study, we aimed to identify
a strategy using food grade materials to selectively and effectively
decrease the allergenic molecules in propolis while preserving its
bioactive components (mainly flavonoids).
Reduction of allergenic compounds in propolis. The aller-
genic components identified in propolis are mainly caffeic acid
derivatives (14) (Fig. 1), amongwhich 3M2B seems to be themost
active (2). Specifically, since the allergenic molecules of propolis
characteristically contain a cinnamoyl ester bond (Fig. 1), we stud-
ied the possibility of employing a bacterial strain, namely, L. hel-
veticus MIMLh5, which we had recently selected over 100 lactic
acid bacteria for its high cinnamoyl esterase activity (12).
To remove allergenicmolecules and tomake themaccessible to
L. helveticus, we first looked for a way to properly mix propolis
with bacterial cells. Propolis is a very dense, resinousmaterial that
is sticky above room temperature and insoluble in water. Propolis
is partially soluble in ethanol, the solvent commonly used in in-
dustry to prepare extracts. For this reason, we tested the stability of
the cinnamoyl esterase activity of MIMLh5 at different ethanol
percentages by using 0.5 mg ml1 chlorogenic acid. Chlorogenic
acid was chosen as a reference molecule in these preliminary ex-
periments because it is a stablemolecule, easy to detect chromato-
graphically, and already successfully employed to quantitatively
study the cinnamoyl esterase activity of lactic acid bacteria (12).
We found that above a concentration of 10% (vol/vol) ethanol,
the enzymatic ability of strain MIMLh5 to hydrolyze chlorogenic
FIG 1 Structural formulas of the molecules constituting the allergenic frac-
tion of propolis. The arrow indicates the chemical bond hydrolyzed by cin-
namoyl esterase activity.
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acid was significantly reduced (data not shown). We then dis-
persed a raw propolis sample in a solution of PBS and 10% (vol/
vol) ethanol (e10PBS) in the presence of different numbers of
MIMLh5 cells (108 to 1014 bacterial cells per g of propolis). After
24 h of incubation at 37°C under constant agitation, we found that
1011 bacterial cells reduced allergenic caffeic acid esters in 1 gram
of raw propolis sample by 43%. With more bacterial cells, the
reduction of allergenic caffeic acid esters increased proportionally,
from 57% with 1012 cells to 67 and 81% reduction when 1013 and
1014 cells, respectively, were employed (Fig. 2). Quantitative anal-
ysis revealed that all the main caffeate esters in propolis decreased
during the biotransformation (Table 1), while the caffeic acid con-
centration increased, confirming that the reduction of caffeates
resulted from the hydrolysis of the cinnamoyl ester bond (Table
1). Bymeans of anHPLC-diode array detector (DAD)method, we
also observed that the flavonoid fraction, considered the main
bioactive component of propolis, was not affected (Table 1).
Improvedpropolis solubilization allowed abigger reduction
of caffeate esters. In the next part of our study, we assessed the
possibility of employing a different solvent to disperse raw propo-
lis sample in order to improve the biotransformation rate. To this
end, we considered PEG 400, for twomain reasons: (i) PEG 400 is
a food-grade additive, recently approved by the European Food
Safety Authority (EFSA) (7), and (ii) PEG 400 reportedly solubi-
lizes hydrophobic molecules, preserving the stability of enzymes
(21). In accordance with the latter statement, the stability of the
cinnamoyl esterase activity of L. helveticus MIMLh5 was unaf-
fected up to 80% (wt/vol) PEG 400 in PBS (data not shown). Next,
we performed biotransformation experiments with 50% PEG 400
instead of ethanol, and we observed a significant improvement in
the reduction of caffeic acid esters. Precisely, under our experi-
mental conditions (i.e., 1 g of propolis in 2 ml of 50% PEG 400),
1011 bacterial cells reduced the allergenicmolecules by 61% (Fig. 2
and Table 1). This result corresponds to a 42% increase in caffeate
ester reduction compared to the same experiment carried out in
10% ethanol. This amelioration of the biotransformation rate was
also maintained in higher numbers of cells; in fact, when 1014
bacterial cells were used, about 98% of caffeic acid esters were
removed in 1 gram of propolis (Fig. 2).
We also tested a propolis sample of different origin, specifi-
cally, fromChina. The reduction of allergenic caffeates in Chinese
propolis occurred only when a greater concentration of PEG 400
was used (80%). Plausibly, this depended on the wax concentra-
tion, which was 60% higher in Chinese than in Italian propolis
(about 40 and 25 g of wax, respectively, per 100 g of raw propolis
[data not shown]). Therefore, optimal experimental conditions
should be set for any specific propolis sample, since its composi-
tion can affect dispersion efficacy.
Different L. helveticus strains display dissimilar abilities to
reduce allergens in propolis.We also tested if diverse strains of L.
helveticus can display different performances during propolis bio-
transformation. We dispelled 1 g of propolis in 2 ml of e10PBS in
the presence of four different L. helveticus strains, namely,
MIMLh5, SLh02, SLh13, and SLh37. L. helveticus SLh02, SLh13,
and SLh37 were included in the study because they are commer-
cial strains with known growth performances at an industrial
level. In particular, strains SLh13 and SLh37 are commercialized
as diary starters and SLh02 as a probiotic. We used 2 1010 bac-
terial cells, because the amount approximately corresponded to
50% activity, and therefore, it was suitable to detect possible dif-
ferences in the biotransformation rate as a function of the bacte-
rium employed. The results showed marked differences among
strains; in particular, two of them, SLh13 and SLh37, displayed
faint activity on propolis, whereas SLh02 and MIMLh5 markedly
reduced caffeate esters (Fig. 3). In a previous report, the cinnam-
oyl esterase activities varied markedly among L. helveticus strains,
andMIMLh5 displayed the highest activity (12). Furthermore, we
observed that the microscopically determined bacterial cell con-
centrationswere the samebefore and after incubationwith propo-
lis. Differences in the biotransformation rates among L. helveticus
strains, therefore, were not a consequence of bacterial growth dis-
similarities during the biotransformation (data not shown).
The antimicrobial activity of MIMLh5-treated (low-aller-
gen) propolis was not significantly dissimilar from that of con-
ventional propolis. In order to confirm that propolis conserved
its beneficial features after treatment with L. helveticus MIMLh5,
TABLE 1 Concentrations of allergenic caffeic acid esters and flavonoids





Biotransformation with 2 109
MIMLh5 cells g1
10% ethanol 50% PEG 400
3M3 2.66 0.11 1.69 0.10 1.53 0.10
3M2 4.33 0.19 2.53 0.14 2.41 0.14
2M2 2.43 0.13 1.52 0.10 1.35 0.09
CABE 6.76 0.41 4.83 0.30 4.36 0.30
CAPE 34.62 1.42 26.01 1.12 21.84 1.10b
Total amt 50.80 2.59 36.58 1.91 31.50 1.73b
Total flavonoids 208.00 11.90 204.00 12.64 212.00 13.81
Flavonoid esters 46.00 2.44 45.08 2.44 46.80 2.55
Caffeic acid 3.80 0.17 4.40 0.19 4.51 0.22
a Data are shown as mg of molecule per g of propolis and describe experiments carried
out using 2 109 cells of MIMLh5 to treat 1 g of propolis dispersed in 10% ethanol or
50% PEG 400. The data represent the means of at least three independent
experiments standard deviations. With the exception of total flavonoids and
flavonoid esters, all molecule concentrations were significantly modified by the
biotransformation (P 0.001; unpaired Student’s t test).
b Statistically significant difference between PEG- and ethanol-treated propolis (P
0.05).
FIG 2 Degradation of caffeic acid esters in raw propolis samples by increasing
concentrations of L. helveticus MIMLh5 cells. Propolis was dispersed in PBS
buffer plus 10% ethanol or 50% PEG 400. The data are reported as means
(three experiments) of the relative amount of all caffeates shown in Fig. 1 
standard deviations.
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we assessed its best-known andmostwidely researched property, i.e.,
the ability to inhibit pathogenicmicroorganisms. In this experiment,
we compared a MIMLh5-treated (low-allergen) propolis alcoholic
extract with an identical preparation that was obtained from non-
treated (conventional) propolis. The antimicrobial activitywas tested
against three bacterial (13 strains) and two fungal (14 strains) species,
which were selected because they are ubiquitous microorganisms,
often involved in opportunistic infections. The MIC50 of the low-
allergenpropolisdidnot significantlydiffer fromthatof conventional
propolis for any of the indicator microorganisms (Table 2). We ob-
served a reducedMIC50 (i.e., stronger antimicrobial ability) only for
low-allergen propolis against S. aureus. Nonetheless, this difference
was not statistically significant (P 0.08) (Table 2). The reduction of
caffeateestersby theactivityof strainL.helveticusMIMLh5, therefore,
didnot result in a lossof antimicrobial activitybypropolis.This result
is in agreement with the flavonoid content, which did not signifi-
cantly change during the biotransformation.
Conclusions.Weproposed a novel biotransformation strategy
to significantly reduce allergenic molecules in propolis without
affecting its bioactive fraction. This method is based on a food-
grade solvent (ethanol or PEG 400) and the cinnamoyl esterase
activity of L. helveticus, a dairy bacterium generally recognized as
safe, included in the EFSA QPS list of microorganisms (6), and
demonstrated to have probiotic properties (13).
A clinical study will be carried out in the near future in order to
confirm that the reduction of caffeate esters by means of the pro-
posed biotransformation can actually result in attenuated allergic
symptoms in propolis-sensitive people. At themoment, this strat-
egy (recently patented [G. M. Ricchiuto, C. Gardana, and S. Gug-
lielmetti, 22 September 2011, international patent application
WO2011/114291]) is under industrial development. The first
promising scale-up experiments suggest that hypoallergenic high-
quality propolis extracts, prepared according to this strategy, will
soon be industrially available.
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